Pernix Therapeutics (PTX) Bullish Stance Reiterated at Needham & Company Following Zohydro ER Deal
Tweet Send to a Friend
Needham & Company analyst Elliot Wilbur reiterated a Strong Buy rating and $16 price target on Pernix Therapeutics (NASDAQ: PTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE